JIGAR ALKOGOLSIZ YOG‘ KASALLIGINI TASHXISLASHDA MIKRORNK NING AHAMIYATI
Keywords:
Jigar alkogolsiz yog‘ kasalligi, jigar steatozi, jigar alkogolsiz steatogepatiti, biomarker, mikroRNK 34.Abstract
Hozirgi kunda jigar alkogolsiz yog‘ kasalligi sog'liqni saqlash tizimining dolzarb muammolaridan biri hisoblanadi. So'nggi yillarda tibbiyotda qo'llaniladigan yangi diagnostika usullari va dori vositalari kashf etilganiga qaramay, JAYKning etiopatogenezi, diagnostikasi, davolash va oldini olish bo'yicha hal qilinmagan ko'plab masalalar mavjud. Jigar alkogolsiz yog‘ kasalligini davolashning asosiy maqsadi kasallikning keyingi bosqichlariga rivojlanishining oldini olish bo'lishi kerak. Klinika amaliyotida ishlatiladigan asosiy jigar testlari kasallik uchun spetsifik emas va har doim ham gistologik o'zgarishlar (jarohatlanish, yallig'lanish, fibroz) haqida aniq ma’lumot bera olmaydi, biopsiya esa jigar kasalliklari diagnostikasida "oltin standart" hisoblanib, JAYK ida kasallikning rivojlanish bosqichlarini, terapevtik ta'sirning samaradorligini belgilaydi. Ushbu maqolada biz klinik amaliyotda JAYK va jigar fibrozi diagnostikasi uchun ishlatiladigan invaziv bo'lmagan biomarkerlar haqida to'xtalib o'tamiz. MikroRNK ning jigar alkogolsiz yog‘ kasalligining rivojlanishidagi potentsial roli muhokama qilinadi.
References
Возможности прогрессирования алкогольного и неалкогольного стеатогепатита в цирроз печени / А. И. Хазанов // РЖГГК. - 2015. № 2. - С. 26-32
Неалкогольный стеатогепатит: патоморфология, клиника и подходы к лечению Богомолов П.О., Павлова Т.В. // Фарматека. – 2003. – №10. – С. 31–39
Роль микро-рнк в формировании и течении заболеваний печени Парпибаева Д.А., Каримов М.Ш., Шукурова Ф.Н., Терапевтический Вестник Узбекистана 2020. № 2
Сравнительный анализ диагностики фиброза печени методом М- и ХЬ-эластометрии у пациентов с хроническим гепатитом С. М.Ю.Галушко, И.Г.Бакулин // Фарматека. - 2016, № 5-16. - С. 40-47
Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. Akuta, N.; Kawamura, Y.; Suzuki, F.; Saitoh, S.; Arase, Y.; Fujiyama, S.; Sezaki, H.; Hosaka, T.; Kobayashi, M.; Suzuki, Y.; et al. BMC Gastroenterol. 2016, 16, 141. [CrossRef]
Bi-directional analysis between fatty liver and cardiovascular disease risk factors, J. Ma [et al.] // Journal of Hepatology. - 2017. - Vol. 66, № 2. - P. 390397
Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. EASL-EASD-EASO. // Journal of Hepatology. -2016. - Vol.64, № 6. - P.1388-1402.).
Circulating microRNA signature in non-alcoholic fatty liver disease: From serum non-coding RNAs to liver histology and disease pathogenesis. Pirola, C.J.; Gianotti, T.F.; Castaño, G.O.; Mallardi, P.; Martino, J.S.; Ledesma, M.M.G.L.; Flichman, D.; Mirshahi, F.; Sanyal, A.J.; Sookoian, S. Gut 2015, 64, 800–812. [Google Scholar] [CrossRef]
Epigenetic regulation of miR-34a expression in alcoholic liver injury. Meng, F.; Glaser, S.S.; Francis, H.; Yang, F.; Han, Y.; Stokes, A.; Staloch, D.; McCarra, J.; Liu, J.; Venter, J.; et al. Am. J. Pathol. 2012, 181, 804–817. [Google Scholar] [CrossRef] [PubMed]
Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD). Del Campo, J.A.; Gallego-Durán, R.; Gallego, P.; Grande, L. Int. J. Mol. Sci. 2018, 19, 911. [Google Scholar] [CrossRef] [PubMed]
Identification of metastasis-related microRNAs in hepatocellular carcinoma , A. Budhu, H.-L. Jia, M. Forgues et al., Hepatology, vol. 47, no. 3, pp. 897–907, 2008.
Increasing prevalence of nonalcoholic steatohepatitis as an indication for liver transplantation // Surgery. R. C. Quillin [et al.] - 2014. - № 156. - P. 1049-1056
Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage.Masarone, M.; Rosato, V.; Aglitti, A.; Bucci, T.; Caruso, R.; Salvatore, T.; Sasso, F.C.; Tripodi, M.F.; Persico, M. PLoS ONE 2017, 12, e0178473. [CrossRef]
Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease // Gastroenterology. P. Angulo [et al.] - 2015. - Vol. 149, № 2. - P. 389-397
MicroRNA-34a and microRNA-34c promote the activation of human hepatic stellate cells by targeting peroxisome proliferator-activated receptor, Li, X.; Chen, Y.; Wu, S.; He, J.; Lou, L.; Ye, W.; Wang, J. γ. Mol. Med. Rep. 2015, 11, 1017–1024. [Google Scholar] [CrossRef] [PubMed]
miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Liu, C.-H.; Ampuero, J.; Gil-Gomez, A.; Montero-Vallejo, R.; Rojas, A.; Munoz-Hernandez, R.; Gallego-Duran, R.; Romero-Gomez, M. J. Hepatol. 2018, 69, 1335–1348. [Google Scholar] [CrossRef] [PubMed]
MicroRNAs in liver disease. Szabo, G.; Bala, S. Nat. Rev. Gastroenterol. Hepatol. 2013, 6, 247–253. [Google Scholar] [CrossRef] [PubMed]
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Cheung, O.; Puri, P.; Eicken, C.; Contos, M.J.; Mirshahi, F.; Maher, J.W.; Kellum, J.M.; Min, H.; Luketic, V.A.; Sanyal, A.J. Hepatology 2008, 48, 1810–1820. [Google Scholar] [CrossRef] [PubMed][Green Version]
Overexpression of acyl-CoA synthetase-1 increases lipid deposition in hepatic (HepG2) cells and rodent liver in vivo. Parkes, H.A.; Preston, E.; Wilks, D.; Ballesteros, M.; Carpenter, L.; Wood, L.; Kraegen, E.W.; Furler, S.M.; Cooney, G.J. Am. J. Physiol. Endocrinol. Metab. 2006, 291, E737–E744. [Google Scholar] [CrossRef] [PubMed]
The miR-34 family in cancer and apoptosis, H. Hermeking, Cell Death and Differentiation, vol. 17, no. 2, pp. 193–199, 2010
